Pipeline Faster, better viral
vaccines and therapeutics.
Our pipeline produces vaccine and viral therapeutic candidates capable of rapidly and specifically responding to our most pressing global health threats.
Infectious
Disease
Our platform makes trial-and-error vaccine development a thing of the past.
Codagenix designs and develops several vaccine candidates in tandem, enabling us to go from genetic sequence of the wild-type virus to viable candidate vaccine or therapeutic in weeks—and faster, if needed, as new outbreak strains are identified.
Program
Pre-
clinicalPreclinical
clinicalPreclinical
Phase
1
1
Phase
2
2
Phase
3
3
Dengue
CDX-DENV
Dengue is a mosquito-borne viral infection that is common in warm, tropical climates. Globally, approximately 2.5 billion people live in dengue-endemic regions. Vaccine development has been challenging as protection against all four dengue virus serotypes is required to avoiding antibody-mediated enhancement of disease. Additionally, current dengue vaccines in development are designed using traditional vectored or serial passage approaches of the historical dengue strain.
Codagenix has leveraged its platform to re-design fully-homologous, contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates.
Codagenix has leveraged its platform to re-design fully-homologous, contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates.
RSV CodaVaxTM – RSV
Adult
Pediatric
Respiratory syncytial virus (RSV) is a leading cause of hospitalization due to acute lower respiratory infection, particularly in infants, young children and elderly adults.
Overcoming long-standing hurdles, our intranasal RSV candidate is genetically stable, induces a meaningful T cell response and is efficacious against wild type challenge in primates. A Phase 1 clinical trial in healthy adults reached its primary endpoint, demonstrating both safety and an anti-RSV cellular immune response. A Phase 1 clinical trial in toddlers and infants is ongoing.
Overcoming long-standing hurdles, our intranasal RSV candidate is genetically stable, induces a meaningful T cell response and is efficacious against wild type challenge in primates. A Phase 1 clinical trial in healthy adults reached its primary endpoint, demonstrating both safety and an anti-RSV cellular immune response. A Phase 1 clinical trial in toddlers and infants is ongoing.
Influenza
Pandemic
Influenza carries a year-round disease burden and can cause severe illness or death, particularly among high-risk populations. The current major vaccines are focused on an antibody response to the highly variable HA protein of influenza.
Codagenix is developing platform designs to address intranasal, pan-type A live-attenuated virus vaccines. Our prototype design, CodaVax™-H1N1, has demonstrated cross-protection in accepted animal models, even against HPAI H5N1. We are currently developing a next-generation platform design that supports rapid swapping of highly variable surface antigens.
Codagenix is developing platform designs to address intranasal, pan-type A live-attenuated virus vaccines. Our prototype design, CodaVax™-H1N1, has demonstrated cross-protection in accepted animal models, even against HPAI H5N1. We are currently developing a next-generation platform design that supports rapid swapping of highly variable surface antigens.
Polio (nOPV)
Surveillance during the global rollout of >1 billion doses of nOPV2 has continued to support, during outbreak response, the enhanced genetic stability that was demonstrated in preclinical and clinical testing of this innovative vaccine, when compared to traditional Sabin oral polio vaccine type 2 (OPV2) use. While this has importantly included an estimated 80% reduction in the emergence of new type 2 circulating vaccine-derived PV (cVDPV2) emergences, it has also revealed that nOPV2 does retain a residual capacity to recombine with close genetic relatives, including Sabin strains and C-cluster non-polio enteroviruses (NPEV-C).
Codagenix is applying its proprietary synthetic biology technology to modify novel oral poliovirus vaccine (nOPV) strains making them less prone to recombination with other enteroviruses and reducing the risk to cause disease or transmission.
Codagenix is applying its proprietary synthetic biology technology to modify novel oral poliovirus vaccine (nOPV) strains making them less prone to recombination with other enteroviruses and reducing the risk to cause disease or transmission.
SARS-CoV-2 (COVID-19)
CoviLivTM
The COVID-19 pandemic has impacted countless lives and caused millions of deaths worldwide.
Our intranasal vaccine candidate CoviLiv is a live-attenuated vaccine, safely enabling a broad antibody and T-cell response.
Our intranasal vaccine candidate CoviLiv is a live-attenuated vaccine, safely enabling a broad antibody and T-cell response.
Yellow Fever
Yellow fever is a viral disease transmitted to humans through bites of infected mosquitoes. The current vaccine is in short or absent supply and relies on antiquated egg-based production. With the habitat of the mosquito vectors expanding into previously temperate latitudes, this disease represents a growing threat to global health.
We have synthesized the vaccine strain and are testing it in vivo to support candidate selection, ultimately aiming for a clinical program utilizing an FDA-accepted surrogate endpoint for registration to allow for accelerated clinical development.
We have synthesized the vaccine strain and are testing it in vivo to support candidate selection, ultimately aiming for a clinical program utilizing an FDA-accepted surrogate endpoint for registration to allow for accelerated clinical development.
Zika
CDX-ZiKV
Zika virus is primarily transmitted by the bite of an infected mosquito, and can also be transmitted through other contacts, including from mother to fetus during pregnancy. This transmission is associated with microencephaly in infants. To date, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection.
Codagenix has leveraged our platform to re-design the Zika vaccine and demonstrate a product that is safe and immunogenic in primates.
Codagenix has leveraged our platform to re-design the Zika vaccine and demonstrate a product that is safe and immunogenic in primates.
Cancer
Virotherapeutics
Shifting the long-standing trajectory of cancer immunotherapies.
Our influenza-based virotherapeutic candidate is the first codon-modified attenuated virus developed to treat cancer.
Program
Pre-
clinicalPreclinical
clinicalPreclinical
Phase
1
1
Phase
2
2
Phase
3
3
Breast Cancer
CodaLyticTM
Breast cancer is one of the leading contributors to cancer-related death worldwide, but remains difficult to target with existing immunotherapies due in part to heterogeneity between breast cancer subtypes and unfavorable tumor microenvironments. Particularly in later stage metastatic settings, there is great unmet need for novel therapy regimens to improve patient outcomes.
Our lead candidate is designed to modulate the tumor microenvironment in multiple ways, leading to reliable anti-tumor efficacy in immune-competent mouse models of breast cancer and triggering several immune effector mechanisms. IND-enabling studies are ongoing.
Our lead candidate is designed to modulate the tumor microenvironment in multiple ways, leading to reliable anti-tumor efficacy in immune-competent mouse models of breast cancer and triggering several immune effector mechanisms. IND-enabling studies are ongoing.
Solid Tumors
CDX-Onc
A variety of solid tumors can benefit from treatment with immunostimulatory viruses, broadening and deepening the patient population benefiting from established immunotherapies. We are actively discovering novel virotherapeutics by leveraging our platform to construct target-specific therapies, focusing on immunologically cold tumors.
Animal Health
The next generation of healthy animals.
Animals are fundamental to the health of people through companionship, high quality nutrition and the control of zoonotic diseases. Codagenix vaccines for agriculture and companion animals will strengthen our food chain, make pets healthier and lower our global reliance on antibiotics.
Area
INDICATION /
PARTNER
PARTNER
Proof of
concept
concept
CLINICAL
DEVELOPMENT
DEVELOPMENT
REGULATORY
MARKET
AUTHORIZATION
AUTHORIZATION
Companion Animal
Canine
Not Public/Not Public
Farm Animal
Swine
Not Public/Not Public
Poultry
Not Public/Not Public
Swine
FMDV/USDA
Cattle
FMDV/USDA
For expanded access, visit our Expanded Access Policy